Rossetti, Barbara Gagliardini, Roberta Meini, Genny Sterrantino, Gaetana Colangeli, Vincenzo Re, Maria Carla Latini, Alessandra Colafigli, Manuela Vignale, Francesca Rusconi, Stefano Micheli, Valeria Di Biagio, Antonio Orofino, Giancarlo Ghisetti, Valeria Fantauzzi, Alessandra Vullo, Vincenzo Grima, Pierfrancesco Francisci, Daniela Mastroianni, Claudio Antinori, Andrea Trezzi, Michele Lisi, Lucia Navarra, Pierluigi Canovari, Benedetta D’Arminio Monforte, Antonella Lamonica, Silvia D’Avino, Alessandro Zazzi, Maurizio Di Giambenedetto, Simona De Luca, Andrea Proportion of individuals without treatment failure over the 48 study weeks by randomization arm in the (a) per protocol population and (b) intention to treat population. <p>Arm S = study arm (switch to maraviroc + darunavir/ritonavir); Arm C = continuation arm (continuation of previous 3-drug therapy).</p> randomized trial Objectives;3- drug ART;CCR 5-tropic virus;plasma drug levels;Femoral bone mineral density;RNA;virologically;maraviroc;week 48. Methods Patients;continuation arm;3- drug therapy;HIV;treatment failure;VF;48- week results;59 continuation arm;study arm;darunavir;QD 2017-11-21
    https://plos.figshare.com/articles/figure/Proportion_of_individuals_without_treatment_failure_over_the_48_study_weeks_by_randomization_arm_in_the_a_per_protocol_population_and_b_intention_to_treat_population_/5621905
10.1371/journal.pone.0187393.g002